Summary of COVID-19 medicines guidance: Neurological disorders

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to coronavirus and neurological disorders.

This page has been put together rapidly in relation to the COVID-19 pandemic.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

NHS England/NHS Improvement: Management of neuro trauma patients

Last updated 19 March 2020

  • This guidance sets out some principles to ensure that essential neurotrauma care continues with the minimum burden on the NHS during the coronavirus pandemic.
  • It includes guidance on how to manage and prioritise the different types of neurotrauma patients, including a flow chart on managing cranial and spinal injury.

 

NHS England/NHS Improvement: After-care needs of inpatients recovering from COVID-19

Last updated 3 August 2020

  • This guidance includes the following therapeutic areas: respiratory, cardiology, neurology, mental health, endocrinology and urology.
  • There is no medication-related information within the neurology, mental health, endocrinology or urology sections.
  • Guidance for management of patients’ physical respiratory needs is given on pages 7-13.
  • Includes recommendations on anticoagulation for patients with pulmonary embolic disease.
  • Reference made to patients requiring cardiac assessment pre-discharge plus plan – with optimisation of medications listed on page 14.

 

Association of British Neurologists: Guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic

Last updated 18 May 2020

  • Detailed guidance is provided on whether to initiate, continue or discontinue disease modifying therapies, based on the increased risk they may confer of viral infection
  • To conserve resource and reduce travel risk, advice is given regarding abbreviated blood monitoring.
  • Should a patient become infected with COVID-19, advice is provided in managing patients and their disease modifying therapies.
  • The recommendations have also been provided in a patient friendly format.

Administration update  (06 August 2020): Administrative amendments made as indicated by red text.